The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

GSK plc (LSE/NYSE:GSK) a annoncé lundi que l'Agence européenne des médicaments (EMA) a accepté d'examiner sa demande d'autorisation de mise sur le marché pour le linerixibat, un traitement expérimenta ...

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...